The purpose of these trials is to enhance an already FDA approved chemotherapy drug called Gemcitabine. Gemcitabine is already used to treat non small-cell lung cancer, ovarian, metastetic breast cancer and pancreatic cancer. It is marketed under the trade name Gemzar and is produced by the Eli Lilly Company.
The problem with Gemcitabine(Gemzar) is that it produces some very nasty side effects, The scientists are attempting to provide a combo treatment that will abate the side effects and prolong the lives of 28 patients with pancreatic cancer.
If the results bear fruit, then LLY will probably want to acquire THLD and cut study costs on future trials. LLY needs a knockout FDA trial on this just as badly as THLD. They have been getting a lot of bad press lately which has caused their stock price to drop a little.
I got on the computer at 4:30 this AM to check for the announcement and was pleased that there was none (like July 17th). It would be nice if they made a good announcement during normal market hours in order to even the playing field.
Gemzar produces severe side effects such as shortness of breath, cramping, nausea, etc. It is a very effective but powerful chemotherapy drug. All chemotherapy drugs, including Glufosfamide, are actually poison in the sense that they are designed to destroy living cells-cancer cells. Unfortunately, they also destroy some good cells(unwanted side effects). They are trying to combine the treatment for these 28 study patients so that they can reduce the amount of Gemmzar which produces more severe side effects than Glufosfamide.